Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report.
- Author:
Haa Na SONG
1
;
Min Gyu KANG
;
Jeong Rang PARK
;
Jin Yong HWANG
;
Jung Hun KANG
;
Won Seop LEE
;
Gyeong Won LEE
Author Information
- Publication Type:Case Report
- Keywords: Sarcoma; Immunotherapy; Pembrolizumab
- MeSH: Drug Therapy; Humans; Immunotherapy; Radiotherapy; Sarcoma
- From:Cancer Research and Treatment 2018;50(4):1458-1461
- CountryRepublic of Korea
- Language:English
- Abstract: Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma.
